Vault-13

Royalty Pharma Sub-Manager, LLC

New York, NY · CIK 2081668 · 13F filing filed 2026-08-21

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

Other 13F filers in this group: Royalty Pharma plc files a notice

$241.9m reported value +40.0% vs Q1 2026
4positions
100.0%in top 10
1 new 0 added 0 reduced 1 sold out vs Q1 2026

This report includes the holdings of 2 other managers that share the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 CYTOKINETICS INC COM NEW CYTK CYTK 980,392 $83.5m34.52% 34.52% UnchangedShares held: Q3 2025 —, Q4 2025 980.4k, Q1 2026 980.4k, Q2 2026 980.4k
2 ZENAS BIOPHARMA INC COM ZBIO ZBIO 2,388,150 $60.6m25.05% 25.05% UnchangedShares held: Q3 2025 —, Q4 2025 1.3m, Q1 2026 2.4m, Q2 2026 2.4m
3 KAILERA THERAPEUTICS INC COMMON STOCK KLRA KLRA 2,455,357 $54.1m22.36% 22.36% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 2.5m
4 BIOHAVEN LTD COM BHVN BHVN 2,936,507 $43.7m18.06% 18.06% UnchangedShares held: Q3 2025 —, Q4 2025 2.9m, Q1 2026 2.9m, Q2 2026 2.9m

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
BIOCRYST PHARMACEUTICALS INC BCRX BCRX 3,846,154 $36.6m3.8m shares